The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors.
 
Nehal Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Davide Melisi
Consulting or Advisory Role - Incyte; iOnctura; SERVIER; Taiho Pharmaceutical; TERUMO
Research Funding - iOnctura
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
Natraj Ammakkanavar
Stock and Other Ownership Interests - Autolus; Cardiff Oncology; Iovance Biotherapeutics; Kura Oncology; Shockwave Medical
Consulting or Advisory Role - AstraZeneca/MedImmune
Speakers' Bureau - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Loxo/Lilly
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Philippe Cassier
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Austin Duffy
Employment - START
Leadership - START
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Merck; Roche
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Loxo; Merck; MERCK (I); Novartis; Pfizer; Pfizer; Quanta Therapeutics; Seagen; Silverback Therapeutics
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); BioTheryX (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Loxo@Lilly (Inst); Merck (Inst); MOMA Therapeutics (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Yutaka Fujiwara
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; MSD; Nippon Kayaku; Ono Pharmaceutical; Otsuka
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novocure (Inst)
 
Paul Oberstein
Consulting or Advisory Role - Amal Therapeutics; AstraZeneca; Ipsen; Janssen Oncology; Loxo/Lilly
Speakers' Bureau - AstraZeneca
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Zai Lab (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Mirati Therapeutics (I); MSD; Pfizer (I); PharmaMar; Roche (I); Sanofi; Servier; Takeda
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD
 
Jennifer Wright
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Aimee Lin
Employment - Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly; Lilly (I)
Patents, Royalties, Other Intellectual Property - Co-inventor on a patent application related to selpercatinib activity
 
Jian Li
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Michael Axelson
Employment - Loxo/Lilly; Tempus
Stock and Other Ownership Interests - Bristol-Myers Squibb; Lilly; Tempus
Travel, Accommodations, Expenses - Loxo/Lilly
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Abbvie; Jazz Pharmaceuticals; Kanaph Therapeutics; OncXerna Therapeutics; SOTIO
Research Funding - 280 BIO (Inst); ABM (Inst); Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); EcoR1 Capital; GlaxoSmithKline (Inst); Guidepoint Inc; Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tango Therapeutics (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)